Research Projects & Grants

For Profit Organization

• P-CDI9CD20-ALLOI-001: Open-Label, Muticenter, Phase 1 Study to Assess the Safety of P-CDl9CD20-ALLO1 in Subjects with Selected Relapsed/Refractory B cell Malignancies, Role: Investigator, Poseida Therapeutics Inc., (12/2025 - 12/2026) Status: Approved
• CYTB323J12201: A Phase 2, open-label study to evaluate the efficacy and safety of rapcabtagene autoleucel in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN), Role: Investigator, Novartis Pharmaceuticals Corporation, (07/2026 - 07/2027) Status: Approved
• ATARA Biotherapeutics, Inc. ATA129-EBV-302: Multicenter, Open Label, Phase 3 study of Tabelecleucel for solid organ or allogeneic hematopoietic cell transplant subjects with Epstein-Barr virus-associated post-transplant lymphoproliferative disease after failure of Rituximab or Rituximab and Chemotherapy (ALLELE study), Role: Investigator, PIERRE FABRE MEDICAMENT, (11/2025 - 11/2026) Status: Approved